Common stock, $0.001 par value
- Symbol
- CTXR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Citius Pharmaceuticals, Inc.
CTXRNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On June 1, 2026, our wholly-owned subsidiary, Citius Oncology, Inc., issued a press release announcing the presentation of clinical data at the Annual Meeting of the American Society of Clinical Oncology. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No.…
Company context
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I - III CTCL after at least one prior systemic therapy. Management estimates the initial CTCL market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets, and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning. For more information, please visit www.citiusonc.com.
Current securities
Historical securities (1)
Recent company filings
- Results of Operations and Financial ConditionOct 26, 2026
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingAug 21, 2026
- 10-Q filingAug 14, 2026
- Results of Operations and Financial ConditionAug 14, 2026
- SCHEDULE 13G/A - filed by CVI Investments, Inc. regarding Citius Pharmaceuticals, Inc.Aug 14, 2026
Registered securities in this filing
Citius Pharmaceuticals, Inc. · 8-K · Filed 2026-06-01
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On June 1, 2026, our wholly-owned
subsidiary, Citius Oncology, Inc., issued a press release announcing the presentation of clinical data at the Annual Meeting of the American
Society of Clinical Oncology. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
99.1 Press release, dated June 1, 2026.
104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
Filed exhibits (1)
EX-99.1 2 ea029290401ex99-1.htm PRESS RELEASE, DATED JUNE 1, 2026 Exhibit 99.1 Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR ® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-treated patients 20.5 months of median progression-free survival observed among 48% of efficacy-evaluable patients achieving clinical benefit (10 of 21) Responses were observed in patients previously treated with immune checkpoint inhibitors, including a 33% objective response rate in patients with relapsed or refractory endometrial cancer CRANFORD, N.J., June 1, 2026 - Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today highlighted Phase 1 clinical data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting evaluat…
Open exhibit ↗